At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VTYX Ventyx Biosciences, Inc.
Post-Mkt 01-07 18:17:50 EST
13.73
+3.68
+36.62%
盘后13.74
+0.01+0.07%
18:17 EST
High15.34Low13.43Vol27.99M
Open15.32D1 Closing10.05Amplitude19.01%
Mkt Cap979.75MTradable Cap735.32MTotal Shares71.36M
T/O393.35MT/O Rate52.26%Tradable Shares53.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ventyx Biosciences Stock Soars 62% After Lilly in Talks to Buy Company for More Than $1 Billion
Reuters  ·  01-07 08:27
Ventyx Biosciences Stock Soars 62% After Lilly in Talks to Buy Company for More Than $1 Billion
BRIEF-Ventyx Biosciences Upon Termination Of Merger Under Specified Circumstances, Co Will Be Required To Pay Eli Lilly Termination Fee Of $44 Million
Reuters  ·  52 minutes ago
BRIEF-Ventyx Biosciences Upon Termination Of Merger Under Specified Circumstances, Co Will Be Required To Pay Eli Lilly Termination Fee Of $44 Million
BRIEF-Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-Mediated Diseases
Reuters  ·  06:17
BRIEF-Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-Mediated Diseases
Ventyx Biosciences: Upon Termination of Merger Under Specified Circumstances, Co Will Be Required to Pay Eli Lilly Termination Fee of $44 Mln
THOMSON REUTERS  ·  06:05
Ventyx Biosciences: Upon Termination of Merger Under Specified Circumstances, Co Will Be Required to Pay Eli Lilly Termination Fee of $44 Mln
Ventyx Biosciences Inc - Transaction Expected to Close in First Half of 2026
THOMSON REUTERS  ·  05:18
Ventyx Biosciences Inc - Transaction Expected to Close in First Half of 2026
Ventyx Biosciences Inc - Lilly Will Acquire All of Outstanding Shares of Ventyx for $14.00 per Share
THOMSON REUTERS  ·  05:18
Ventyx Biosciences Inc - Lilly Will Acquire All of Outstanding Shares of Ventyx for $14.00 per Share
Ventyx Biosciences Inc - Proposed Deal for Equity Value of Approximately $1.2 Bln
THOMSON REUTERS  ·  05:18
Ventyx Biosciences Inc - Proposed Deal for Equity Value of Approximately $1.2 Bln
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
Reuters  ·  02:51
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
Crude Oil Down 2%; ISM Services PMI Surges In December
Benzinga  ·  01:25
Crude Oil Down 2%; ISM Services PMI Surges In December
Stock Track | Ventyx Biosciences Soars 36.72% Intraday as Eli Lilly Eyes $1 Billion Acquisition
Stock Track  ·  01-07 23:12
Stock Track | Ventyx Biosciences Soars 36.72% Intraday as Eli Lilly Eyes $1 Billion Acquisition
UBS Initiates Ventyx Biosciences at Buy With $20 Price Target
MT Newswires Live  ·  01-07 23:09
UBS Initiates Ventyx Biosciences at Buy With $20 Price Target
BRIEF-Companies Are Discussing A Deal In Which Eli Lilly Would Pay $14 A Share In Cash For Ventyx- WSJ
Reuters  ·  01-07 22:40
BRIEF-Companies Are Discussing A Deal In Which Eli Lilly Would Pay $14 A Share In Cash For Ventyx- WSJ
Companies Are Discussing a Deal in Which Eli Lilly Would Pay $14 a Share in Cash for Ventyx- WSJ
THOMSON REUTERS  ·  01-07 22:39
Companies Are Discussing a Deal in Which Eli Lilly Would Pay $14 a Share in Cash for Ventyx- WSJ
Stocks to Watch Wednesday: BP, Netflix, Paramount, Strategy -- WSJ
Dow Jones  ·  01-07 22:36
Stocks to Watch Wednesday: BP, Netflix, Paramount, Strategy -- WSJ
BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods
Reuters  ·  01-07 22:26
BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods
Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell
MT Newswires Live  ·  01-07 22:11
Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell
BUZZ-U.S. STOCKS ON THE MOVE-Colgate, Strategy, AAR Corp
Reuters  ·  01-07 20:09
BUZZ-U.S. STOCKS ON THE MOVE-Colgate, Strategy, AAR Corp
U.S. Stocks to Watch: Strategy, Sandisk, Ventyx Biosciences, Mobileye, and More
Dow Jones  ·  01-07 18:51
U.S. Stocks to Watch: Strategy, Sandisk, Ventyx Biosciences, Mobileye, and More
Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition
Stock Track  ·  01-07 17:12
Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition
Ventyx Biosciences Inc : UBS Initiates Coverage With Buy Rating; Target Price $20
THOMSON REUTERS  ·  01-07 17:12
Ventyx Biosciences Inc : UBS Initiates Coverage With Buy Rating; Target Price $20

Introduction

Company Name.
Ventyx Biosciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Issue price:
--